elagolix

an orally available nonpeptide GnRH antagonist

Also Known As:

Orilissa; R-(+)-4-(2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)-1-phenylethylamino)butyrate; elagolix sodium

Networked: 106 relevant articles (27 outcomes, 39 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Halogenated Hydrocarbons: 42
    - Fluorinated Hydrocarbons: 4
      - elagolix: 106
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - elagolix: 106

Experts

1.	Soliman, Ahmed M: 18 articles (10/2021 - 04/2016)
2.	Archer, David F: 12 articles (01/2022 - 01/2017)
3.	Chwalisz, Kristof: 10 articles (01/2021 - 07/2013)
4.	Taylor, Hugh S: 10 articles (01/2021 - 01/2017)
5.	Mostafa, Nael M: 9 articles (12/2022 - 10/2018)
6.	Shebley, Mohamad: 9 articles (12/2022 - 01/2020)
7.	Winzenborg, Insa: 9 articles (12/2022 - 10/2018)
8.	Agarwal, Sanjay K: 9 articles (10/2021 - 01/2018)
9.	Ng, Juki: 9 articles (01/2021 - 01/2017)
10.	Owens, Charlotte D: 8 articles (01/2022 - 11/2018)

Related Diseases

1.	Endometriosis 12/01/2019 - "Treatment with elagolix improved endometriosis-related workplace and household productivity impairments. " 09/01/2017 - "Efficacy of elagolix in the treatment of endometriosis." 01/01/2021 - "Data were pooled from two 6-month, placebo-controlled, phase 3 studies (Elaris Endometriosis [EM]-I and II) in which 2 doses of elagolix were evaluated (150 mg once daily and 200 mg twice daily). " 01/01/2021 - "The BMD, CTX, and P1NP predictions by the QSP model were validated against observed data from four phase III clinical trials of elagolix in premenopausal women with endometriosis. " 12/01/2020 - "Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real-World Population."
2.	Leiomyoma (Uterine Fibroids) 01/01/2022 - "In both comparisons, elagolix has reduced the mean percentage change in uterine and fibroid volume, improved symptoms, and health-related quality of life. " 01/01/2021 - "Simulations suggest that untreated premenopausal women with uterine fibroids (UFs) from elagolix phase III clinical trials (median age 43 years [minimum 25-maximum 53]) lose 0.6% FN-BMD each year up to menopausal age. " 12/01/2022 - "Interdisciplinary model-informed drug development for extending duration of elagolix treatment in patients with uterine fibroids." 01/01/2019 - "Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data." 01/01/2019 - "One of them, Elagolix, is in the early stages of testing in women with fibroids. "
3.	Pain (Aches) 01/01/2021 - "Patient-reported reduction in pain at month 3 was significant across all subgroups taking elagolix 200 mg BID, and significant across most subgroups with elagolix 150 mg QD. " 01/01/2020 - "However, the benefits of elagolix extend beyond reducing pain symptoms. " 01/01/2019 - "As the degree of ovarian suppression obtained with elagolix is dose-dependent, pain relief may be achieved by modulating the level of hypo-oestrogenism while limiting side effects. " 03/01/2014 - "Placebo patients were rerandomized to elagolix and elagolix patients continued their dosing assignment for 12 additional weeks; the primary efficacy measure was changed from baseline in the monthly mean numerical rating scale for pain at week 12. " 01/01/2021 - "This review provides an overview of elagolix, highlighting currently available treatment options and the application of this new treatment for women with endometriosis-associated pain."
4.	Menorrhagia 11/01/2023 - "Elagolix 150 mg once-daily monotherapy significantly improved heavy menstrual bleeding associated with uterine leiomyomas compared with placebo in premenopausal patients. " 01/01/2022 - "Elagolix is effective and safe for treating menorrhagia in women with uterine fibroid. " 11/01/2023 - "To evaluate the safety and efficacy of elagolix 150 mg once-daily monotherapy in patients with heavy menstrual bleeding associated with uterine leiomyomas. " 11/01/2023 - "Low-Dose Elagolix for the Treatment of Heavy Menstrual Bleeding in Patients With Uterine Leiomyomas: A Randomized Controlled Trial." 01/01/2022 - "Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis."
5.	Dysmenorrhea (Menstrual Pain) 01/01/2017 - "In Elaris EM-I, the percentage of women who had a clinical response with respect to dysmenorrhea was 46.4% in the lower-dose elagolix group and 75.8% in the higher-dose elagolix group, as compared with 19.6% in the placebo group; in Elaris EM-II, the corresponding percentages were 43.4% and 72.4%, as compared with 22.7% (P<0.001 for all comparisons). " 10/15/2020 - "Clinical trials showed that elagolix is effective in treating dysmenorrhea and non-menstrual pain that is secondary to endometriosis. " 01/01/2021 - "Elagolix was effective in reducing dysmenorrhea and NMPP, and improving HRQoL, compared with placebo across numerous subgroups of women with various baseline characteristics, covering a broad segment of the endometriosis disease and patient types. " 01/01/2021 - "Following 6 months of elagolix treatment, women who still menstruated had a lower proportion of menstrual period days with moderate or severe dysmenorrhea compared with placebo, demonstrating pain reduction despite continued menses. " 01/01/2021 - "Compared with placebo at month 6, elagolix-treated women had a significantly lower mean (standard deviation (SD)) percentage of menstrual period days with moderate or severe dysmenorrhea (elagolix 150 mg QD = 52.4 (38.9), p = 0.002; elagolix 200 mg BID = 38.5 (43.6), p < 0.001, placebo = 61.3 (33.7)) and a significantly lower mean (SD) percentage of nonmenstrual (nonbleeding) days with moderate or severe nonmenstrual pelvic pain (elagolix 150 mg QD = 31.1 (35.8), p < 0.001; elagolix 200 mg BID = 19.7 (29.9), p < 0.001; placebo = 35.6 (33.9)). "

Related Drugs and Biologics

1.	Gonadotropin-Releasing Hormone (GnRH)
2.	Estradiol (Delestrogen)
3.	Norethindrone Acetate (Norlutate)
4.	relugolix
5.	linzagolix
6.	Plant Preparations (Preparation, Plant)
7.	Levonorgestrel (Plan B)
8.	Contraceptive Agents (Contraceptives)
9.	Opioid Analgesics (Opioids)
10.	Analgesics (Analgesic Drugs)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Duration of Therapy
4.	Contraindications